Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 Smart Ways To Buy Cheap Stocks With Confidence

By Josh Enomoto, InvestorPlace Contributor

With the novel coronavirus upturning our paradigm, cheap stocks have become one of the hottest topics thanks to their accessibility. Here are seven tips on how to approach this market segment smartly.

Piedmont Lithium Stock Is Just a Bit Player in the EV Narrative

By Josh Enomoto, InvestorPlace Contributor

With demand from EV powerhouse Tesla forecasted to skyrocket, Piedmont Lithium stock likewise shot to the moon. But before you dive in, make sure you test drive PLL’s fundamentals.

Eastman Kodak Is Banking on a Low-Probability Lifeline

By Josh Enomoto, InvestorPlace Contributor

Kodak stock is still hovering at a relatively rich premium due to hopes of a government-sponsored recovery. But this narrative is risky.

An Executive Order Alone Won’t Save Westwater Resources

By Josh Enomoto, InvestorPlace Contributor

WWR stock received tremendous enthusiasm thanks to President Trump’s executive order but will the momentum last?

Why a Blue Wave May Signal More Green for Sunrun

By Josh Enomoto, InvestorPlace Contributor

While millennials may vote Democrat, the higher taxes could send them to sunnier tax-friendly states, boding very well for RUN stock.

7 Monster Growth Stocks With Double-Digit Upside

By Josh Enomoto, InvestorPlace Contributor

With several growth stocks encountering a steep discount from the coronavirus panic, many early speculators have benefitted tremendously. However, those getting in late to the game still have a chance at upside.

Why Catalyst Pharmaceuticals Stock Is Feeling the ‘Bern’

By Josh Enomoto, InvestorPlace Contributor

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio

By Josh Enomoto, InvestorPlace Contributor

With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.

Why the FDA’s Inquiry of Inovio Is More Critical Than You Think

By Josh Enomoto, InvestorPlace Contributor

INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.

Big Data Doesn’t Exempt Palantir Technologies From Big Problems

By Josh Enomoto, InvestorPlace Contributor

There’s no doubt that big data has changed our world and PLTR stock is levered to this still rapidly growing sector. However, headwinds associated with the pandemic may impede Palantir Technologies’ progress.

Load More